We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Medical Mktg | LSE:MMG | London | Ordinary Share | GB0004150685 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 3.75 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
Hot Features
Premium
TIDMMMG
RNS Number : 3854T
Medical Marketing Int'l Group PLC
04 June 2009
FUNDING UPDATE
4 June 2009 - Medical Marketing International Group plc ("MMI" or the "Company")
(AIM:MMG), the life sciences company focused on the development of drugs for
cancer, today provides an update on the funding arrangements of the Company.
At the time of its interim results in December 2008, MMI announced that it was
funded until the end of June 2009. Following the advancement of the Company's
cost-cutting program, MMI today announces that it now has funds sufficient to
last until late summer. The Board continues to discuss further funding options
and will provide a further update when appropriate.
The Company also reports that it has not yet resolved the outstanding employment
claims of David Best.
Enquiries:
+-----------------------------------------+-----------------------------------------+
| Medical Marketing International Group | Tel: +44 (0) 1223 477 677 |
| plc | |
| Phil Cartmell, Non-executive Chairman | |
| Mark Burton, Chief Technical Officer | |
| Rob Sprawson, Chief Financial Officer | |
+-----------------------------------------+-----------------------------------------+
| | |
+-----------------------------------------+-----------------------------------------+
| FinnCap | Tel: +44 (0)20 7600 1658 |
| Sam Smith/Charlie Cunningham | |
+-----------------------------------------+-----------------------------------------+
| | |
+-----------------------------------------+-----------------------------------------+
| Financial Dynamics | Tel: +44 (0)20 7831 3113 |
| Emma Thompson | |
+-----------------------------------------+-----------------------------------------+
About MMI
Medical Marketing International Group plc ("MMI") is a life sciences company
that identifies, acquires and develops world-class compounds and technologies
for the treatment of cancer. The Company manages the preclinical and early
clinical development of drug candidates before pursuing licensing partners to
manage late-stage development. Please visit www.mmigroup.co.uk for further
information.
Notwithstanding the inclusion on this release by MMI of a website address and/or
another electronic address, MMI does not accept any notices or any other
documents or communication via its website or other electronic address. All such
notices, documents or communication shall be in hard copy format only.
Accordingly the provisions of section 333 Companies Act 2006 allowing persons to
communicate with MMI electronically shall not apply to MMI.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCILFVFRFISIIA
1 Year Medical Mktg Chart |
1 Month Medical Mktg Chart |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
